A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate alzheimer-type dementia: The SCALEX study;Estudio comparativo de la efectividad y tolerabilidad de un procedimiento de escalado lento de dosis de rivastigmina en pacientes con demencia tipo Alzheimer leve o moderada: Estudio SCALEX

Revista de Neurologia

Volumn 46, Issue 9, 2008, Pages 517-524

  Agüera Ortiz, Luis F ^a   Ramos Garcia M ^b   Gobartt, A L ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c Medical Affairs Department   (Spain)

Author keywords

Alzheimer's disease; Anticholinesterases; Dose escalation; Effectiveness; Rivastigmine; Tolerability

Indexed keywords

RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BARTHEL INDEX; CHI SQUARE TEST; CLINICAL PRACTICE; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; OUTPATIENT CARE; PRESCRIPTION; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 44449106504     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4609.2008183     Document Type: Article

References (20)

1. Cobb JL, Wolf PA, Au R, White R, D'Agostino RB. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology 1995; 45: 1707-12.
2. Agüero-Torres H, Fratiglioni L, Guo Z. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999; 52: 737-43.
3. Gandía L, Álvarez RM, Hernández-Guijo JM, González-Rubio JM, De Pascual-Del Castillo R, Rojo J, et al. Anticolinesterásicos en el tratamiento de la enfermedad de Alzheimer. Rev Neurol 2006; 42: 471-7.
4. Bryant J, Clegg A, Nicholson T, Mclntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5: 1-137.
5. Lamb HM, Goa KL. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001; 19: 303-18.
6. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-69.
7. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
8. Anand R, Gharabawi G. Clinical development of Exelon (ENA-713): the ADENA® Programme. J Drug Dev Clin Pract 1996; 8: 9-14.
9. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-41.
10. Rösler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-years treatment with the cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer's disease. Behav Neurol 1998; 11: 211-6.
11. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmina in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000; 2: 68-72.
12. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA-713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
13. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international, randomised, controlled trial. Br Med J 1999; 318: 633-8.
14. Spencer CMN, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drug Aging 1998; 13: 391-411.
15. World Health Organization. Clasificación ATC (Anatómico- Terapéutico-Química de Medicamentos). Oslo: WHO-Collaborating Centre for drugs Statistics Methodology; 2001.
16. Cummings J, Lefevre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69 (Suppl 1): S10-3.
17. Lefevre G, Pommier F, Sedek G, Allison M, Huang HL, Kiese B, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008; 48: 246-52.
18. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69 (Suppl 1): S23-8.
19. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease -rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
20. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69 (Suppl 1): S14-22.